BioVie to Present Phase 2 ADDRESS-LC Results for Bezisterim in Long COVID

BioVie Inc., a clinical-stage biopharmaceutical company, is set to present the results of its Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID. The presentation, scheduled for September 23, 2026, at 11:00 a.m. ET, will be hosted by RedChip Companies as part of an exclusive live investor webinar.

Cuong Do, BioVie’s President and CEO, will provide an in-depth review of the topline results from the ADDRESS-LC trial. The trial assessed bezisterim’s potential in addressing key Long COVID symptoms, including fatigue, post-exertional malaise, and cognitive impairment. According to the press release, 21 out of 22 clinical endpoints favored bezisterim treatment.

The presentation will also explore how the ADDRESS-LC findings support BioVie’s scientific thesis that chronic inflammation and associated insulin resistance may contribute to neurological dysfunction. Do will discuss the Long COVID findings alongside BioVie’s recently reported Phase 2 Parkinson’s disease results, highlighting the potential therapeutic benefits of bezisterim across multiple central nervous system (CNS) conditions.

BioVie’s lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. The company is also studying bezisterim for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

The webinar will also address the commercial opportunity for bezisterim, given the lack of FDA-approved therapies specifically for Long COVID and the potentially large affected population. Attendees will have the opportunity to ask questions during a live Q&A session with BioVie’s management.

To register for the free webinar, interested parties can visit the provided link. The event is aimed at providing investors with a deeper understanding of BioVie’s progress and the potential of bezisterim in addressing neurological disorders and Long COVID.

BioVie Inc. is focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim, is being studied for its potential in Long COVID, while the company is also advancing BIV201, a continuous infusion of terlipressin treatment for liver disease, which has received FDA Orphan and Fast Track designations.